Monte Rosa Therapeutics, Inc. (GLUE) Q1 2024 Earnings
GLUE·Reported May 9, 2024·Before market open
Monte Rosa Therapeutics, Inc. reported Q1 2024 revenue of $1.1M, missed analyst consensus of $1.4M by $336.0K. Diluted EPS came in at $-0.53, beat the $-0.57 consensus by $0.04.
Revenue
$1.1Mmissed by $336.0K
Consensus: $1.4MDiluted EPS
$-0.53beat by $0.04
Consensus: $-0.57
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Monte Rosa Therapeutics, Inc.'s Q1 2024 earnings report.
Monte Rosa Therapeutics, Inc. (GLUE) reported Q1 2024 earnings on May 9, 2024 before market open.
Monte Rosa Therapeutics, Inc. reported revenue of $1.1M and diluted EPS of $-0.53 for Q1 2024.
Revenue missed the consensus estimate of $1.4M by $336.0K. EPS beat the consensus estimate of $-0.57 by $0.04.
You can read the 10-Q periodic report (0000950170-24-056288) directly on SEC EDGAR. The filing index links above go to sec.gov.